FIELD: medicine.
SUBSTANCE: invention refers to biotechnology, more specifically to agents increasing a glycolysis process in somatic cells, and can be used in medicine.
EFFECT: effective glycolysis acceleration in the somatic cells with using the Enterococcus faecium M strain, the based composition or Bilactin preparation.
13 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND AGENT FOR TREATING VIRUS HEPATITIS BASED ON Enterococcus faecium M (VKPM B-3490) AND Enterococcus faecium M-3185 (VKPM B-3491) STRAINS | 2007 |
|
RU2445107C2 |
| METHOD FOR METABOLIC PROCESSES INTENSIFYING IN LIVER | 2003 |
|
RU2342152C2 |
| PREPARATION SHOWING IMMUNOSTIMULATING EFFECT | 1994 |
|
RU2101020C1 |
| STRAIN OF BACTERIUM STREPTOCOCCUS FAECIUM USED FOR CONTROL OF DYSBACTERIOSIS IN AGRICULTURE ANIMALS | 1993 |
|
RU2152433C1 |
| METHOD OF ENHANCING EFFICACY OF VACCINE AND APPLICATION OF PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM SF68 FOR ENHANCING EFFICACY OF VACCINE | 2006 |
|
RU2411038C2 |
| APPLICATION OF PROBIOTIC STRAIN OF ENTEROCOCCUS FAECIUM L-3 MICROORGANISM FOR NEURODEGENERATIVE DISEASES TREATMENT | 2014 |
|
RU2642246C2 |
| ENTEROCOCCUS STRAIN ENTEROCOCCUS FAECIUM L-3 FOR THE TREATMENT AND PREVENTION OF BACTERIAL AND VIRAL INFECTIONS USING THERAPEUTIC AND PROPHYLACTIC AGENTS AND FOOD PRODUCTS MADE ON ITS BASIS AND A METHOD OF CULTIVATING THE ENTEROCOCCUS STRAIN ENTEROCOCCUS FAECIUM L-3 | 2022 |
|
RU2800359C1 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
| METHOD FOR INTROGRESSION OF PATHOGENIC STREPTOCOCCUS GENES IN CHROMOSOMAL DNA OF PROBIOTIC STRAIN OF ENTEROCOCCUS FAECIUM L3 FOR EXPRESSION IN PILES | 2015 |
|
RU2640250C2 |
| METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
